Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2009

01.12.2009 | Gynecologic Oncology

Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in the Treatment of Stage I Endometrial Cancer: Results From the ILIADE Randomized Study

verfasst von: Mauro Signorelli, Andrea Alberto Lissoni, Gennaro Cormio, Dionyssios Katsaros, Antonio Pellegrino, Luigi Selvaggi, Fabio Ghezzi, Giovanni Scambia, Paolo Zola, Roberto Grassi, Rodolfo Milani, Raffaella Giannice, Giovanna Caspani, Costantino Mangioni, Irene Floriani, Eliana Rulli, Roldano Fossati, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Five percent to 20% of stage I endometrial cancer patients undergoing total abdominal hysterectomy and bilateral salpingo-oophorectomy develop vaginal and pelvic recurrences. Adjuvant radiotherapy can improve locoregional control but not survival. This randomized trial aimed to determine whether a modified radical (Piver–Rutledge class II) hysterectomy can improve survival and locoregional control compared to the standard extrafascial (Piver–Rutledge class I) hysterectomy.

Methods

Eligible patients (n = 520) with stage I endometrial cancer were randomized to class I or class II hysterectomy. Primary endpoint was overall survival.

Results

The median length of parametria and vagina removed were 15 and 5 vs. 20 mm and 15 mm for class I and class II hysterectomy, respectively (P > 0.001). Operating time and blood loss were statistically significantly higher for class II hysterectomy. At a median follow-up of 70 months, 51 patients had died. Five-year disease-free and overall survival were similar between arms (87.7 and 88.9% in the class I arm and 89.7 and 92.2% in the class II arm, respectively). The unadjusted hazard ratios for recurrence was 0.91 (95% confidence interval, 0.55–1.51, P = 0.72), and the hazard ratio for death was 0.77 (95% confidence interval, 0.44–1.33, P = 0.35).

Conclusions

Class II hysterectomy did not improve locoregional control and survival compared to class I hysterectomy, but when an adequate vaginal cuff transection is not feasible with class I hysterectomy, a modified radical hysterectomy allows to obtain an optimal vaginal and pelvic control of disease with a minimal increase in surgical morbidity.
Literatur
1.
2.
Zurück zum Zitat Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynaecol. 1980;56:419–27. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynaecol. 1980;56:419–27.
3.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–11.CrossRefPubMed Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–11.CrossRefPubMed
4.
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL, Gynecologic Oncology Group, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed Keys HM, Roberts JA, Brunetto VL, Gynecologic Oncology Group, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed
5.
Zurück zum Zitat The ASTEC/EN.5 Writing Committee on behalf of the ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46.CrossRef The ASTEC/EN.5 Writing Committee on behalf of the ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46.CrossRef
6.
Zurück zum Zitat Mariani A, Dowdy SC, Keeney GL, et al. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005;97:820–7.CrossRefPubMed Mariani A, Dowdy SC, Keeney GL, et al. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005;97:820–7.CrossRefPubMed
7.
Zurück zum Zitat Elliott P, Green D, Coates A, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 1994;4:84–93.CrossRefPubMed Elliott P, Green D, Coates A, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 1994;4:84–93.CrossRefPubMed
8.
Zurück zum Zitat Alektiar KM, McKee A, Venkatraman E, et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys. 2002;53:707–13.PubMed Alektiar KM, McKee A, Venkatraman E, et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys. 2002;53:707–13.PubMed
9.
Zurück zum Zitat Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al.; Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22:1234–41.CrossRefPubMed Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al.; Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22:1234–41.CrossRefPubMed
10.
Zurück zum Zitat Scholten AN, van Putten WL, Beerman H, PORTEC Study Group, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834–8.PubMed Scholten AN, van Putten WL, Beerman H, PORTEC Study Group, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834–8.PubMed
11.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC, PORTEC Study Group, et al. The postoperative radiation therapy in endometrial carcinoma. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2001;51:1246–55.PubMed Creutzberg CL, van Putten WL, Koper PC, PORTEC Study Group, et al. The postoperative radiation therapy in endometrial carcinoma. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2001;51:1246–55.PubMed
12.
Zurück zum Zitat Ng TY, Perrin LC, Nicklin JL, Cheuk R, Crandon AJ. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. Gynecol Oncol. 2000;79:490–4.CrossRefPubMed Ng TY, Perrin LC, Nicklin JL, Cheuk R, Crandon AJ. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. Gynecol Oncol. 2000;79:490–4.CrossRefPubMed
13.
Zurück zum Zitat Chadha M, Nanavati PJ, Liu P, Fanning J, Jacobs A. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy (review). Gynecol Oncol. 1999;75:103–7.CrossRefPubMed Chadha M, Nanavati PJ, Liu P, Fanning J, Jacobs A. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy (review). Gynecol Oncol. 1999;75:103–7.CrossRefPubMed
14.
Zurück zum Zitat Horowitz NS, Peters WA 3rd, Smith MR, et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002;99:235–40.CrossRefPubMed Horowitz NS, Peters WA 3rd, Smith MR, et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002;99:235–40.CrossRefPubMed
15.
Zurück zum Zitat Röper B, Astner ST, Heydemann-Obradovic A, et al. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol. 2007;107:541–8.CrossRefPubMed Röper B, Astner ST, Heydemann-Obradovic A, et al. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol. 2007;107:541–8.CrossRefPubMed
16.
Zurück zum Zitat Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol. 2005;97:887–92.CrossRefPubMed Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol. 2005;97:887–92.CrossRefPubMed
17.
Zurück zum Zitat Rittenberg PV, Lotocki RJ, Heywood MS, Jones KD, Krepart GV. High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone. Gynecol Oncol. 2003;89:288–94.CrossRefPubMed Rittenberg PV, Lotocki RJ, Heywood MS, Jones KD, Krepart GV. High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone. Gynecol Oncol. 2003;89:288–94.CrossRefPubMed
18.
Zurück zum Zitat Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial (abstract LBA5503). Paper presented at: 2008 ASCO Annual Meeting, Chicago, IL. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial (abstract LBA5503). Paper presented at: 2008 ASCO Annual Meeting, Chicago, IL.
19.
Zurück zum Zitat Greven KM, Lanciano RM, Herbert SH, Hogan PE. Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation. Int J Radiat Oncol Biol Phys. 1991;21:919–23.PubMed Greven KM, Lanciano RM, Herbert SH, Hogan PE. Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation. Int J Radiat Oncol Biol Phys. 1991;21:919–23.PubMed
20.
Zurück zum Zitat Anderson JM, Stea B, Hallum AV, Rogoff E, Childers J. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys. 2000;46:417–25.CrossRefPubMed Anderson JM, Stea B, Hallum AV, Rogoff E, Childers J. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys. 2000;46:417–25.CrossRefPubMed
21.
Zurück zum Zitat Piver MS, Rutledge FN, Smith JP. Five classes of extended hysterectomy of women with cervical cancer. Obstet Gynecol. 1974;44:265–70.PubMed Piver MS, Rutledge FN, Smith JP. Five classes of extended hysterectomy of women with cervical cancer. Obstet Gynecol. 1974;44:265–70.PubMed
22.
Zurück zum Zitat Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet. 1997;350(9077):535–40.CrossRefPubMed Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet. 1997;350(9077):535–40.CrossRefPubMed
23.
Zurück zum Zitat Javert CT, Douglas RG. Treatment of endometrial adenocarcinoma; a study of 381 cases at the New York Hospital; a preliminary report. Am J Roentgenol Radium Ther Nucl Med. 1956;75:508–14.PubMed Javert CT, Douglas RG. Treatment of endometrial adenocarcinoma; a study of 381 cases at the New York Hospital; a preliminary report. Am J Roentgenol Radium Ther Nucl Med. 1956;75:508–14.PubMed
24.
Zurück zum Zitat Rutledge FN. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol. 1974;2:331–47.CrossRefPubMed Rutledge FN. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol. 1974;2:331–47.CrossRefPubMed
25.
Zurück zum Zitat Pagel J, Bock JE. Endometrial cancer. A review. Dan Med Bull. 1984;31:333–45.PubMed Pagel J, Bock JE. Endometrial cancer. A review. Dan Med Bull. 1984;31:333–45.PubMed
26.
Zurück zum Zitat Sartori E, Gadducci A, Landoni F, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001;11:430–7.CrossRefPubMed Sartori E, Gadducci A, Landoni F, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001;11:430–7.CrossRefPubMed
27.
Zurück zum Zitat Cohn DE, Woeste EM, Cacchio S, et al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol. 2007;109:1062–7.PubMed Cohn DE, Woeste EM, Cacchio S, et al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol. 2007;109:1062–7.PubMed
28.
Zurück zum Zitat Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol. 1999;74:80–5.CrossRefPubMed Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol. 1999;74:80–5.CrossRefPubMed
29.
Zurück zum Zitat Maggino T, Romagnolo C, Zola P, et al. An analysis of approaches to the treatment of endometrial cancer in Western Europe: a CTF study. Eur J Cancer. 1995;31:1993–7.CrossRef Maggino T, Romagnolo C, Zola P, et al. An analysis of approaches to the treatment of endometrial cancer in Western Europe: a CTF study. Eur J Cancer. 1995;31:1993–7.CrossRef
30.
Zurück zum Zitat Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.CrossRef Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.CrossRef
31.
Zurück zum Zitat Huh WK, Straughn JM Jr, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007;17:886–9.CrossRefPubMed Huh WK, Straughn JM Jr, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007;17:886–9.CrossRefPubMed
32.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC, PORTEC Study Group, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Onco.l 2003;89:201–9.CrossRefPubMed Creutzberg CL, van Putten WL, Koper PC, PORTEC Study Group, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Onco.l 2003;89:201–9.CrossRefPubMed
33.
Zurück zum Zitat Arndt-Miercke H, Martin A, Briese V, et al. Transection of vaginal cuff is an independent prognostic factor in stage I endometrial cancer. Eur J Surg Oncol. 2008;34:241–6.PubMed Arndt-Miercke H, Martin A, Briese V, et al. Transection of vaginal cuff is an independent prognostic factor in stage I endometrial cancer. Eur J Surg Oncol. 2008;34:241–6.PubMed
34.
Zurück zum Zitat Landoni F, Maneo A, Cormio G, et al. Class II versus class III radical hysterectomy in stage Ib–IIa cervical cancer: a prospective randomized study. Gynecol Oncol. 2001;80:3–12.CrossRefPubMed Landoni F, Maneo A, Cormio G, et al. Class II versus class III radical hysterectomy in stage Ib–IIa cervical cancer: a prospective randomized study. Gynecol Oncol. 2001;80:3–12.CrossRefPubMed
35.
Zurück zum Zitat Raspagliesi F, Ditto A, Fontanelli R, et al. Type II versus type III nerve-sparing radical hysterectomy: comparison of lower urinary tract dysfunctions. Gynecol Oncol. 2006;102:256–62.CrossRefPubMed Raspagliesi F, Ditto A, Fontanelli R, et al. Type II versus type III nerve-sparing radical hysterectomy: comparison of lower urinary tract dysfunctions. Gynecol Oncol. 2006;102:256–62.CrossRefPubMed
36.
Zurück zum Zitat Zola P, Maggino T, Sacco M, et al. Prospective multicenter study on urologic complications after radical surgery with or without radiotherapy in the treatment of stage IB–IIA cervical cancer. Int J Gynecol Cancer. 2000;10:59–66.CrossRefPubMed Zola P, Maggino T, Sacco M, et al. Prospective multicenter study on urologic complications after radical surgery with or without radiotherapy in the treatment of stage IB–IIA cervical cancer. Int J Gynecol Cancer. 2000;10:59–66.CrossRefPubMed
Metadaten
Titel
Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in the Treatment of Stage I Endometrial Cancer: Results From the ILIADE Randomized Study
verfasst von
Mauro Signorelli
Andrea Alberto Lissoni
Gennaro Cormio
Dionyssios Katsaros
Antonio Pellegrino
Luigi Selvaggi
Fabio Ghezzi
Giovanni Scambia
Paolo Zola
Roberto Grassi
Rodolfo Milani
Raffaella Giannice
Giovanna Caspani
Costantino Mangioni
Irene Floriani
Eliana Rulli
Roldano Fossati, MD
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0736-6

Weitere Artikel der Ausgabe 12/2009

Annals of Surgical Oncology 12/2009 Zur Ausgabe

Translational Research and Biomarkers

RGS16 Is a Marker for Prognosis in Colorectal Cancer

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.